Halozyme Therapeutics (HALO) Tops Q2 EPS by 30c ; Offers Guidance
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $112.45 +2.53%
EPS Growth %: +30.8%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +30.8%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $1.54, $0.30 better than the analyst estimate of $1.24. Revenue for the quarter came in at $326 million versus the consensus estimate of $286.01 million.
GUIDANCE:
Halozyme Therapeutics sees FY2025 EPS of $6.00-$6.40, versus the consensus of $5.40. Halozyme Therapeutics sees FY2025 revenue of $1.27-1.35 billion, versus the consensus of $1.25 billion.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale files for IPO, seeks NYSE listing under ticker NSCL
- Trump on Xi visit: we get along very well
- Dianthus Therapeutics (DNTH) files mixed shelf
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
